2. Search Result
Search Result
Results for "

Neuro-2a

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

1

Peptides

4

Natural
Products

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-151527
    PI3K/Akt/CREB activator 1
    2 Publications Verification

    		 Akt PI3K Epigenetic Reader Domain Neurological Disease
    PI3K/Akt/CREB activator 1 (compound AE-18) is a potent, orally active PI3K/Akt/CREB activator. PI3K/Akt/CREB activator 1 promotes neuronal proliferation, induced differentiation of Neuro-2a cells into a neuron-like morphology, and accelerated the establishment of axon-dendrite polarization of primary hippocampal neurons through upregulating brain-derived neurotrophic factor via the PI3K/Akt/CREB pathway. PI3K/Akt/CREB activator 1 can be used in research of vascular dementia (VaD) .
    PI3K/Akt/CREB activator 1
  • HY-114926
    KT185

    		MAGL Neurological Disease
    KT185 is an orally-bioavailable, brain-penetrant and selective ABHD6 inhibitor, with an IC50 0.21 nM in Neuro2A cells .
    KT185
  • HY-120177
    KT182

    		MAGL Others
    KT182 is a potent and selective inhibitor of α/β-hydrolase domain containing 6 (ABHD6), with an IC50 of 0.24 nM in Neuro2A cells .
    KT182
  • HY-120215
    KT203

    		MAGL Metabolic Disease
    KT203 is a potent and selective inhibitor of α/β-hydrolase domain containing 6 (ABHD6), with an IC50 of 0.31 nM in Neuro2A cells .
    KT203
  • HY-119910
    (E)-Aminoquinol

    XIB4035

    		 GDNF Receptor Neurological Disease
    (E)-Aminoquinol (XIB4035) is a GFRα-1 agonist. (E)-Aminoquinol has mimic neurotrophic effects of GDNF, and induces Ret autophosphorylation in Neuro-2A cells. (E)-Aminoquinol can be used for research of Parkinson’s disease .
    (E)-Aminoquinol
  • HY-124503
    Longanlactone

    		Trk Receptor Neurological Disease
    Longanlactone is a natural pyrrole-lactone alkaloid that can be used as a neurotrophic agent. Longanlactone increases BDNF gene expression in neuro2a cells .
    Longanlactone
  • HY-126981
    Sarasinoside B1

    		Others Cancer
    Sarasinoside B1 is a glycoside compound. Sarasinoside B1 exhibits moderate cytotoxicity against Neuro-2a and HepG2 cell lines (IC50=~5-18 μM).
    Sarasinoside B1
  • HY-119910A
    Aminoquinol

    (E/Z)-XIB4035

    		 GDNF Receptor Neurological Disease
    Aminoquinol is a GFRα-1 agonist. Aminoquinol exhibits neurotrophic effects similar to GDNF and induces Ret autophosphorylation in Neuro-2A cells. Aminoquinol can be used in research related to Parkinson's disease .
    Aminoquinol
  • HY-119910B
    Aminoquinol phosphate

    (E/Z)-XIB4035 phosphate

    		 GDNF Receptor Neurological Disease
    Aminoquinol ((E/Z)-XIB4035) phosphate is a GFRα-1 agonist. Aminoquinol phosphate exhibits neurotrophic effects similar to GDNF and induces Ret autophosphorylation in Neuro-2A cells. Aminoquinol phosphate can be used in research related to Parkinson's disease .
    Aminoquinol phosphate
  • HY-119910C
    Aminoquinol triphosphate

    (E/Z)-XIB4035 triphosphate

    		 GDNF Receptor Neurological Disease
    Aminoquinol ((E/Z)-XIB4035) phosphate is a GFRα-1 agonist. Aminoquinol phosphate exhibits neurotrophic effects similar to GDNF and induces Ret autophosphorylation in Neuro-2A cells. Aminoquinol phosphate can be used in research related to Parkinson's disease .
    Aminoquinol triphosphate
  • HY-139182
    MAGL-IN-3

    		Endogenous Metabolite Metabolic Disease
    CAY10762 is an inhibitor of monoacylglycerol lipase (MAGL; IC50=34.1 nM). It reduces hydrogen peroxide-induced lactate dehydrogenase (LDH) release from Neuro2a cells when used at a concentration of 1 μM. CAY10762 (10 mg/kg) increases levels of 2-arachidonoyl glycerol in mouse brain.
    MAGL-IN-3
  • HY-112828
    LEI105

    		DAGL Neurological Disease Metabolic Disease Inflammation/Immunology
    LEI105 is a potent, highly selective and reversible dual diacylglycerol lipase (DAGL)-α/DAGL-β inhibitor. LEI105 reduces 2-arachidonoylglycerol levels in Neuro2A cells. LEI105 also reduces cannabinoid CB1-receptor-mediated short-term synaptic plasticity in a mouse hippocampal slice model. LEI105 is promising for research of diseases, such as obesity, related metabolic disorders and neuroinflammation .
    LEI105
  • HY-169831
    HUP-55

    		α-synuclein Neurological Disease
    HUP-55 is a prolyl endopeptidase inhibitor (IC50 = 5 nM). HUP-55 reduces the dimerization of α-synuclein in Neuro2a cells and induces autophagy (Autophagy) in HEK293 cells. It also decreases the increase in reactive oxygen species (ROS) production induced by hydrogen peroxide in SH-SY5Y cells at a concentration of 10 μM. In a mouse Parkinson’s disease model, HUP-55 (10 mg/kg) improves motor function (reduces the use frequency of the impaired paw) and decreases the levels of harmful oligomers of α-synuclein in the striatum caused by overexpression of α-synuclein .
    HUP-55
  • HY-138967
    BRF110

    		Nuclear Hormone Receptor 4A/NR4A RAR/RXR Neurological Disease
    BRF110 is the selective, orally active rexinoid for Nurr1-RXRα, that selectively activates the Nurr1-RXRα heterodimer with an EC50 of 0.9 μM in SH-SY5Y. BRF110 upregulates the expression of BDNF, exhibits neuroprotective activity against MPP+ induced toxicity. BRF110 can cross blood-brain barrier .
    BRF110
  • HY-P10397
    YHIEPV

    rALP-2, Rubisco anxiolytic-like peptide 2

    		 iGluR Neurological Disease Metabolic Disease
    YHIEPV (rALP-2, Rubisco anxiolytic-like peptide 2) is a potent and orally active peptide. YHIEPV shows anxiolytic effects. YHIEPV increases leptin sensitivity to exert its anti-obesity effects [2].
    YHIEPV
  • HY-N6691R
    Veratridine (Standard)

    		Sodium Channel Neurological Disease
    Veratridine (Standard) is the analytical standard of Veratridine. This product is intended for research and analytical applications. Veratridine (3-Veratroylveracevine) is a plant neurotoxin, a voltage-gated sodium channels (VGSCs) agonist. Veratridine inhibits the peak current of Nav1.7, with an IC50 of 18.39?μM. Veratridine regulates sodium ion channels mainly by activating sodium ion channels, preventing channel inactivation and increasing sodium ion flow [2].
    Veratridine (Standard)
  • HY-N6691
    Veratridine
    3 Publications Verification

    3-Veratroylveracevine

    		 Sodium Channel Neurological Disease
    Veratridine (3-Veratroylveracevine) is a plant neurotoxin, a voltage-gated sodium channels (VGSCs) agonist. Veratridine inhibits the peak current of Nav1.7, with an IC50 of 18.39 µM. Veratridine regulates sodium ion channels mainly by activating sodium ion channels, preventing channel inactivation and increasing sodium ion flow [2].
    Veratridine
  • HY-115498
    ARN14494

    		Apoptosis NO Synthase Interleukin Related COX Neurological Disease Inflammation/Immunology
    ARN14494 is a potent and selective serine palmitoyltransferase (SPT) inhibitor, with an IC50 of 27.3 nM. ARN14494 affects the CNS in terms of anti-inflammation and neuroprotection. ARN14494 protects neurons from β-amyloid 1-42-induced neurotoxicity through a variety of mechanisms, including anti-oxidation, anti-apoptosis, and anti-inflammation. ARN14494 can be used for Alzheimer’s disease research .
    ARN14494
  • HY-146679
    HDAC6-IN-6

    		HDAC Amyloid-β Cholinesterase (ChE) Neurological Disease
    HDAC6-IN-6 (compound 6a) is a potent and BBB-penetrated HDAC6 inhibitor, with an IC50 of 0.025 μM. HDAC6-IN-6 exhibits strong inhibitory activity against Aβ1-42 self-aggregation and AChE, with IC50 values of 3.0 and 0.72 μM. HDAC6-IN-6 can enhance neurite outgrowth without significant neurotoxicity .
    HDAC6-IN-6
  • HY-146678
    HDAC6-IN-5

    		HDAC Amyloid-β Cholinesterase (ChE) Neurological Disease
    HDAC6-IN-5 (compound 11b) is a potent and BBB-penetrated HDAC6 inhibitor, with an IC50 of 0.025 μM. HDAC6-IN-5 exhibits strong inhibitory activity against Aβ1-42 self-aggregation and AChE, with IC50 values of 3.0 and 0.72 μM. HDAC6-IN-5 can enhance neurite outgrowth without significant neurotoxicity .
    HDAC6-IN-5
  • HY-B1081A
    Oxidopamine hydrobromide
    Maximum Cited Publications
    26 Publications Verification

    6-Hydroxydopamine hydrobromide; 6-OHDA hydrobromide

    		 Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase Neurological Disease Cancer
    Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome [2] .
    Oxidopamine hydrobromide
  • HY-B1081
    Oxidopamine hydrochloride
    Maximum Cited Publications
    26 Publications Verification

    6-Hydroxydopamine Hydrochloride

    		 Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase Neurological Disease Cancer
    Oxidopamine (6-OHDA) hydrochloride is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrochloride is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrochloride promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrochloride can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome [2] .
    Oxidopamine hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: